ALRN-6924 is the only non-small molecule MDM2-p53 inhibitor that has been evaluated in clinical trials involving breast cancer patients with wild-type p53 (NCT03725436), however, no results have been posted thus far. This evidence concerns the gene TP53 and breast carcinoma.